CSL Limited Sponsored ADR CSLLY | OTC
Company Overview:
10 Year CSLLY Performance Metrics:
CSLLY Dividend Payments & Yield
CSLLY Dividends Info:
Projected Future Returns & Dividends for CSLLY
Based on past 10-year performance, here are CSLLY growth metrics:
Share price CAGR of +5.97%
Dividend CAGR of +3.21%
Using CSLLY CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| CSLLY (DRIP) | CSLLY - No DRIP | |
|---|---|---|
| Current Price | $34.67 | $34.67 |
| Start Shares | 288.43 | 288.43 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 354.75 | 288.43 |
| Dividends Payment | $0.56 | $0.56 |
| Annual Dividends | $394 | $320 |
| Yield on cost | 3.94% | 3.20% |
| Share Price | $61.93 | $61.93 |
| Total Dividends | $3,018 | $2,704 |
| Final Value | $21,969 | $20,566 |
NOTE: Above numbers are our estimate based on CSLLY's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
CSL Limited Sponsored ADR (CSLLY) had its IPO on , and is traded on OTC stock exchange.
CSL Limited Sponsored ADR represents shares of the Australian biotechnology company CSL Limited that are traded on American stock exchanges. CSL Limited is renowned for its focus on developing and manufacturing innovative biopharmaceutical products, especially in the fields of immunotherapy and protein-based therapies. The company's product portfolio includes a wide range of medicines used to treat bleeding disorders, immune deficiencies, and neurological disorders, serving critical medical needs globally. By issuing sponsored ADRs, CSL Limited extends its reach to U.S. investors, allowing them to access its shares without needing to purchase them directly on Australian exchanges. This ADR plays a significant role in expanding the company’s investor base, thereby increasing its capital inflows and enhancing liquidity. CSL's operations greatly impact the healthcare sector, providing advanced therapeutics that drive progress in medical science and improve patient outcomes around the world. As a leader in the biotechnology industry, CSL is committed to sustaining its growth through R&D and strategic expansion, solidifying its position as a key player in the global pharma and biotech markets.
CSLLY website: https://www.csl.com
DCF model unavailable for CSLLY — no fundamentals on file (ETFs and funds are not modelable).
